tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Breuer K et al. Safety and efficacy of topical calcineurin inhibitors in the treatment of childhood atopic dermatitis. 2005 Am J Clin Dermatol pmid:15799678
Gupta AK and Versteeg SG Topical Treatment of Facial Seborrheic Dermatitis: A Systematic Review. 2017 Am J Clin Dermatol pmid:27804089
Kalavala M and Dohil MA Calcineurin inhibitors in pediatric atopic dermatitis: a review of current evidence. 2011 Am J Clin Dermatol pmid:21067248
Yang LP and Curran MP Spotlight on topical pimecrolimus in pediatric atopic dermatitis. 2010 Am J Clin Dermatol pmid:20509720
Ozden MG et al. Topical pimecrolimus 1% cream for resistant seborrheic dermatitis of the face: an open-label study. 2010 Am J Clin Dermatol pmid:20000875
Patel TS et al. Cancer concerns with topical immunomodulators in atopic dermatitis: overview of data and recommendations to clinicians. 2007 Am J Clin Dermatol pmid:17645374
Mertens JS et al. Morphea and Eosinophilic Fasciitis: An Update. 2017 Am J Clin Dermatol pmid:28303481
Frankel HC and Qureshi AA Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis. 2012 Am J Clin Dermatol pmid:22263704
Kroft EB et al. Efficacy of topical tacrolimus 0.1% in active plaque morphea: randomized, double-blind, emollient-controlled pilot study. 2009 Am J Clin Dermatol pmid:19354332
Tjioe M et al. Topical macrolide immunomodulators: a role in the treatment of vitiligo? 2006 Am J Clin Dermatol pmid:16489839
Valdivielso-Ramos M et al. Significant improvement in extensive lichen sclerosus with tacrolimus ointment and PUVA. 2008 Am J Clin Dermatol pmid:18429647
Wellington K and Noble S Pimecrolimus: a review of its use in atopic dermatitis. 2004 Am J Clin Dermatol pmid:15663345
Cook BA and Warshaw EM Role of topical calcineurin inhibitors in the treatment of seborrheic dermatitis: a review of pathophysiology, safety, and efficacy. 2009 Am J Clin Dermatol pmid:19222250
Ingram JR et al. Impact of topical calcineurin inhibitors on quality of life in patients with atopic dermatitis. 2009 Am J Clin Dermatol pmid:19489656
Reitamo S et al. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. 2002 Am J Clin Dermatol pmid:12113647
Wellington K and Jarvis B Spotlight on topical pimecrolimus in atopic dermatitis. 2002 Am J Clin Dermatol pmid:12113651
Lübbe J et al. Safety, efficacy, and dosage of 1% pimecrolimus cream for the treatment of atopic dermatitis in daily practice. 2006 Am J Clin Dermatol pmid:16605292
Ellis CN et al. Cost effectiveness of management of mild-to-moderate atopic dermatitis with 1% pimecrolimus cream in children and adolescents 2-17 years of age. 2006 Am J Clin Dermatol pmid:16605293
Wollina U The role of topical calcineurin inhibitors for skin diseases other than atopic dermatitis. 2007 Am J Clin Dermatol pmid:17492844
Kasper RC et al. Anetoderma arising in cutaneous B-cell lymphoproliferative disease. 2001 Am J Dermatopathol pmid:11285407
Roche, FDA announce new drug-interaction warnings for mibefradil. 1998 Am J Health Syst Pharm pmid:9492249
Ku YM et al. Compatibility of tacrolimus injection with cimetidine hydrochloride injection in 0.9% sodium chloride injection. 1995 Am J Health Syst Pharm pmid:8528874
Greanya ED et al. Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. 2012 Am J Health Syst Pharm pmid:22215359
Heavner MS et al. Clinical outcomes associated with conversion from brand-name to generic tacrolimus in hospitalized kidney transplant recipients. 2013 Am J Health Syst Pharm pmid:23943182
Curtin BF et al. Unusually late-onset mycophenolate mofetil-related colitis. 2014 Am J Health Syst Pharm pmid:25320135
Bonhomme-Faivre L et al. Effect of the ABCB1 3435C>T polymorphism on tacrolimus concentrations and dosage requirements in liver transplant recipients. 2009 Am J Health Syst Pharm pmid:19729569
Lee JH et al. Stability of tacrolimus solutions in polyolefin containers. 2016 Am J Health Syst Pharm pmid:26796907
Tacrolimus. 2001 Am J Health Syst Pharm pmid:11794952
Lee B et al. Appropriate timing of tacrolimus concentration measurements in the emergency department. 2016 Am J Health Syst Pharm pmid:27543574
Jacobson PA et al. Stability of tacrolimus in an extemporaneously compounded oral liquid. 1997 Am J Health Syst Pharm pmid:9117806
Utecht KN et al. Effects of genetic polymorphisms on the pharmacokinetics of calcineurin inhibitors. 2006 Am J Health Syst Pharm pmid:17106006
Kelly PA et al. Tacrolimus: a new immunosuppressive agent. 1995 Am J Health Syst Pharm pmid:7552894
MacDonald AS and Sketris IS Tacrolimus in transplantation. 1995 Am J Health Syst Pharm pmid:7552906
Johnson CE et al. Stability of tacrolimus with morphine sulfate, hydromorphone hydrochloride, and ceftazidime during simulated intravenous coadministration. 1999 Am J Health Syst Pharm pmid:10030533
Pennington CA and Park JM Sublingual tacrolimus as an alternative to oral administration for solid organ transplant recipients. 2015 Am J Health Syst Pharm pmid:25631834
Tsapepas DS et al. Managing the atazanavir-tacrolimus drug interaction in a renal transplant recipient. 2011 Am J Health Syst Pharm pmid:21200061
Myers AL et al. Stability of tacrolimus injection diluted in 0.9% sodium chloride injection and stored in Excel bags. 2016 Am J Health Syst Pharm pmid:27919876
Grouzmann E et al. Misleading tacrolimus concentration value in blood taken from a catheter used for tacrolimus administration. 2008 Am J Health Syst Pharm pmid:18216007
Taormina D et al. Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers. 1992 Am J Hosp Pharm pmid:1373936
Min DI et al. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. 1992 Am J Hosp Pharm pmid:1282779
Tacrolimus introduced for use in liver transplantation. 1994 Am J Hosp Pharm pmid:7524317
Przepiorka D et al. Blood tacrolimus concentration unchanged by plasmapheresis. 1994 Am J Hosp Pharm pmid:7524318
Matsunami H et al. New technique for measuring tacrolimus concentrations in blood. 1994 Am J Hosp Pharm pmid:7510929
Pezze JL and Whiteman K Transplantation's newest weapon FK 506. 1991 Am J Nurs pmid:1716857
Yang GS et al. Intratympanic immunosuppressives for prevention of immune-mediated sensorineural hearing loss. 2000 Am J Otol pmid:10912694
Tulaci KG et al. The effect of tacrolimus on facial nerve injury: Histopathological findings in a rabbit model. Am J Otolaryngol pmid:27465503
Knott PD et al. Induction with T-cell receptor antibody leads to long-term laryngeal allograft function. 2008 Nov-Dec Am J Otolaryngol pmid:19144301
Laifer SA et al. Pregnancy after cardiac transplantation. 1994 Am J Perinatol pmid:7519426
Lee J et al. Inpatient rehabilitation challenges in a quadrimembral amputee after bilateral hand transplantation. 2011 Am J Phys Med Rehabil pmid:21765280
Reams BD and Palmer SM Sublingual tacrolimus for immunosuppression in lung transplantation: a potentially important therapeutic option in cystic fibrosis. 2002 Am J Respir Med pmid:14720063
Moon BJ et al. Effect of chronic rhinosinusitis on liver transplant patients. 2009 Sep-Oct Am J Rhinol Allergy pmid:19807981
Shin JH et al. The effect of topical FK506 (tacrolimus) in a mouse model of allergic rhinitis. 2012 Mar-Apr Am J Rhinol Allergy pmid:22487280
Vearrier D et al. Mutism and persistent dysarthria due to tacrolimus-based immunosuppression following allogeneic liver transplantation. 2011 Am J Ther pmid:20535006
Yang A and Wang B Sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids: focus on acute rejection, patient and graft survival. Am J Ther pmid:23921809
Pariser D Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption. 2009 May-Jun Am J Ther pmid:19262357
Sathyan S et al. Prevention of recurrent episodes of rhabdomyolysis with tacrolimus in a transplant recipient with myopathy. Am J Ther pmid:23429166
Liu JY et al. Tacrolimus Versus Cyclosporine as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation. Am J Ther pmid:25299636
Haroon N et al. Tacrolimus Toxicity With Minimal Clinical Manifestations: A Case Report and Literature Review. Am J Ther pmid:25730156
Nunokawa T et al. Late-onset scleroderma renal crisis induced by tacrolimus and prednisolone: a case report. Am J Ther pmid:22836123
Liu JY et al. Sirolimus Versus Tacrolimus as Primary Immunosuppressant After Renal Transplantation: A Meta-Analysis and Economics Evaluation. Am J Ther pmid:25569597
Cohen SM Current immunosuppression in liver transplantation. 2002 Mar-Apr Am J Ther pmid:11897926
Yousuf Bhat Z et al. Colchicine-Induced Myopathy in a Tacrolimus-Treated Renal Transplant Recipient: Case Report and Literature Review. Am J Ther pmid:24732905
Azizian M et al. Augmentation of ischemia/reperfusion injury to endothelial cells by cyclosporin A. 2004 Am Surg pmid:15156953
Henderson CN et al. Continuous Abdominal Irrigation for Treatment of Tertiary Peritonitis in the Immunosuppressed Patient after Solid Organ Transplant: A Novel Approach. 2017 Am Surg pmid:28424115
Rojas-García P et al. Breast fibroadenomas associated with immunosuppressive drugs. 2010 Am Surg pmid:21418766
Kodama M et al. FK506 therapy of experimental autoimmune myocarditis after onset of the disease. 1993 Am. Heart J. pmid:7504393
Chieffo A et al. Histopathology of clinical coronary restenosis in drug-eluting versus bare metal stents. 2009 Am. J. Cardiol. pmid:19962471
Chang RK et al. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. 1998 Am. J. Cardiol. pmid:9604971
Klauss V et al. Cyclosporine versus tacrolimus (FK 506) for prevention of cardiac allograft vasculopathy. 2000 Am. J. Cardiol. pmid:10955391
Herzberg GZ et al. Usefulness of tacrolimus versus cyclosporine after pediatric heart transplantation. 1998 Am. J. Cardiol. pmid:9723652
Hisamura F et al. Synergistic effect of green tea polyphenols on their protection against FK506-induced cytotoxicity in renal cells. 2008 Am. J. Chin. Med. pmid:18543393
Chung SY et al. Ginkgo biloba leaf extract (EGb761) combined with neuroprotective agents reduces the infarct volumes of gerbil ischemic brain. 2006 Am. J. Chin. Med. pmid:17080546
Stickle DF et al. Effects of sterilizing gamma irradiation on bloodspot newborn screening tests and whole blood cyclosporine and tacrolimus measurements. 2003 Am. J. Clin. Pathol. pmid:12580001
Wang E et al. Pseudo-Pelger-Huët anomaly induced by medications: a clinicopathologic study in comparison with myelodysplastic syndrome-related pseudo-Pelger-Huët anomaly. 2011 Am. J. Clin. Pathol. pmid:21228370
Burke MT et al. Expression of Bcl-xL and Mcl-1 in the nonmelanoma skin cancers of renal transplant recipients. 2015 Am. J. Clin. Pathol. pmid:25780003
Lower DR et al. Comparison of CEDIA FK506 assay with HPLC/MS/MS in a large cohort of pediatric patients. 2013 Am. J. Clin. Pathol. pmid:23690122
Rudi J et al. Prevalence of serum antibodies to Helicobacter pylori and to CagA protein in liver transplant recipients. 1997 Am. J. Gastroenterol. pmid:9317070
Van Thiel DH et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7532912
Baumgart DC et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. 2006 Am. J. Gastroenterol. pmid:16573777
Sandborn WJ Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. 1997 Am. J. Gastroenterol. pmid:9149205
Van Thiel DH et al. Tacrolimus: a potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. 1995 Am. J. Gastroenterol. pmid:7537444
Fellermann K et al. Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). 1998 Am. J. Gastroenterol. pmid:9772045
Nara M et al. Effect of oral itraconazole on the pharmacokinetics of tacrolimus in a hematopoietic stem cell transplant recipient with CYP3A5*3/*3. 2010 Am. J. Hematol. pmid:20568249
Lekakis LJ et al. BK virus nephropathy after allogeneic stem cell transplantation: a case report and literature review. 2009 Am. J. Hematol. pmid:19208419
Hammerstrom AE et al. Tacrolimus-associated posterior reversible encephalopathy syndrome in hematopoietic allogeneic stem cell transplantation. 2013 Am. J. Hematol. pmid:23460378
Abdel-Azim H et al. Unrelated donor hematopoietic stem cell transplantation for the treatment of non-malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. 2015 Am. J. Hematol. pmid:26242764
Uehara T et al. Successful control of Epstein-Barr virus (EBV)-infected cells by allogeneic nonmyeloablative stem cell transplantation in a patient with the lethal form of chronic active EBV infection. 2004 Am. J. Hematol. pmid:15282671
Nakamae H et al. Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation. 2006 Am. J. Hematol. pmid:16755559
Bolaños-Meade J et al. Lymphocytic pneumonitis as the manifestation of acute graft-versus-host disease of the lung. 2005 Am. J. Hematol. pmid:15929116
Ninan MJ and Datta YH Post-transplant lymphoproliferative disorder presenting as multiple myeloma. 2010 Am. J. Hematol. pmid:20578201
Mach-Pascual S et al. Microangiopathic hemolytic anemia complicating FK506 (tacrolimus) therapy. 1996 Am. J. Hematol. pmid:8701950
Uehara T et al. A successful second unrelated BMT (UBMT) from a different unrelated donor to treat ALL that relapsed after the initial UBMT. 2002 Am. J. Hematol. pmid:12221672
Cohen DL et al. Pulse wave analysis to assess vascular compliance changes in stable renal transplant recipients. 2004 Am. J. Hypertens. pmid:15001192
Zhang W and Victor RG Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension. 2000 Am. J. Hypertens. pmid:10981550
Taler SJ et al. Loss of nocturnal blood pressure fall after liver transplantation during immunosuppressive therapy. 1995 Am. J. Hypertens. pmid:7544983
Choudhry S et al. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial. 2009 Am. J. Kidney Dis. pmid:19268410
Haas M et al. Smooth muscle-specific actin levels in the urine of renal transplant recipients: correlation with cyclosporine or tacrolimus nephrotoxicity. 1999 Am. J. Kidney Dis. pmid:10401019
Hricik DE Safety and efficacy of TOR inhibitors and other immunosuppressive regimens in African-American renal transplant recipients. 2001 Am. J. Kidney Dis. pmid:11583939
Pescovitz MD and Govani M Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients. 2001 Am. J. Kidney Dis. pmid:11583940
Asif A et al. Peritoneoscopic placement of peritoneal dialysis catheter and bowel perforation: experience of an interventional nephrology program. 2003 Am. J. Kidney Dis. pmid:14655200